Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 8, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Vunakizumab: First Approval.

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand. dru@adis.com.

|November 4, 2024

Summary

This summary is machine-generated.

Vunakizumab, an anti-interleukin-17A antibody, received China approval in August 2024 for moderate-to-severe plaque psoriasis. This marks a significant milestone for treating IL-17-mediated autoimmune diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Icotrokinra: First Approval.

Drugs·2026

Same author

Ferric Maltol: Pediatric First Approval.

Paediatric drugs·2026

Same author

Sevabertinib: First Approval.

Drugs·2026

Same author

Retlirafusp Alfa: First Approval.

Drugs·2026

Same author

Zeprumetostat: First Approval.

Drugs·2025

Same author

Brensocatib: First Approval.

Drugs·2025

Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026

Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026

Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026

Same journal

Relacorilant: First Approval.

Drugs·2026

Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026

Same journal

Linerixibat: First Approval.

Drugs·2026

See all related articles

Area of Science:

Immunology
Dermatology
Pharmacology

Background:

Interleukin-17A (IL-17A) is a key cytokine in the pathogenesis of autoimmune diseases.
Targeting the IL-17 pathway has emerged as a promising therapeutic strategy for conditions like psoriasis.
Vunakizumab is a novel humanized monoclonal antibody developed for IL-17A inhibition.

Purpose of the Study:

To summarize the key development milestones of vunakizumab.
To highlight the regulatory approval process and its significance.
To provide an overview of vunakizumab's journey towards market authorization for psoriasis.

Main Methods:

Review of preclinical and clinical development data.
Analysis of regulatory submission and approval timelines.

More Related Videos

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

Related Experiment Videos

Last Updated: Jun 8, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

Summary of the drug's mechanism of action and target indication.

Main Results:

Vunakizumab, a subcutaneous anti-IL-17A antibody, has been developed by Suzhou Suncadia Biopharmaceutical.
The drug targets autoimmune diseases driven by the IL-17 pathway, including psoriasis.
In August 2024, vunakizumab received its first approval in China for moderate-to-severe plaque psoriasis.

Conclusions:

The approval of vunakizumab in China represents a significant advancement in the treatment of plaque psoriasis.
This milestone underscores the therapeutic potential of IL-17A inhibition in autoimmune conditions.
Vunakizumab's development journey highlights progress in targeted biologic therapies for dermatological diseases.